Skip to main content
Board of Directors
A word from the CEO
The AGIR program
Platform of Expertise
News & events
To answer health and environmental challenges
Next generation anti-infectives
Active ingredients of natural origin
DEINOVE is now ready to start Phase II clinical trial for its antibiotic compound DNV3837
Having reached a sufficient number of clinical centers, Phase II clinical trial testing the...
The mechanism of action of Phytoene applied to dermocosmetic now determined and promoted at the NYSCC Suppliers' day
DEINOVE has developed a unique bioproduction process that leads to the first 100% pure Phytoene...
More press releases
Annual Shareholders’ meeting
The annual Shareholders’ meeting will be held on May 20, 2019 in Paris
Find all the information and forms for voting by post or by proxy
In the Medias
Labiotech.eu | Life at its Limits: Meet the Extremophiles Being Embraced by the Biotech Industry
French biotech Deinove has an enviable collection of thousands of species of rare microbes that the company has been collecting since it...
Arte | Antibiotiques, la fin du miracle ?
Le XXIe siècle marquera-t-il la fin de l’ère des antibiotiques, ramenant la médecine deux cents ans en arrière ? Malgré leurs efforts, les...
More press coverage